Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at Oppenheimer

Key Points

• Oppenheimer has initiated coverage of Monopar Therapeutics (NASDAQ:MNPR) with an "outperform" rating and a price target of $77.00, indicating a potential upside of 113.53%.
• Multiple research firms, including HC Wainwright and Cantor Fitzgerald, have assigned ratings to Monopar Therapeutics, with consensus showing a Buy rating and a price target averaging $69.57.
• Insider trading reveals significant stock sales, with directors reducing their ownership by over 40% after selling shares at around $40.00.

Stock analysts at Oppenheimer initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set an "outperform" rating and a $77.00 price target on the stock. Oppenheimer's price target indicates a potential upside of 113.53% from the stock's current price.

Several other research firms have also recently commented on MNPR. HC Wainwright began coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a "buy" rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Raymond James Financial began coverage on Monopar Therapeutics in a research note on Tuesday. They set a "strong-buy" rating and a $80.00 price objective for the company. Finally, Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $69.57.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $36.06 on Wednesday. The company has a market capitalization of $222.49 million, a PE ratio of -10.80 and a beta of 1.20. Monopar Therapeutics has a one year low of $2.29 and a one year high of $54.30. The business has a 50 day simple moving average of $37.95 and a 200 day simple moving average of $36.69.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.12. Equities analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at $459,440. The trade was a 43.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director owned 5,173 shares in the company, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,504 shares of company stock worth $1,700,160. Corporate insiders own 20.50% of the company's stock.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently modified their holdings of MNPR. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics in the second quarter valued at about $34,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics during the first quarter worth about $44,000. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter worth about $45,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the second quarter worth about $80,000. Finally, New York State Common Retirement Fund bought a new stake in Monopar Therapeutics during the second quarter worth about $104,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.